Epigral Plans Investor Roadshow in Mumbai Amidst Q3 Challenges

Epigral Limited will hold a non-deal roadshow for institutional investors in Mumbai on April 8, 2026. The company plans to use the event for one-on-one meetings to present its latest financial performance and discuss its corporate strategy. Epigral has stated that no non-public price-sensitive information will be shared. This outreach follows a difficult Q3 FY26, which saw both revenue and profit fall significantly, alongside reduced EBITDA margins.

Investor Outreach Amidst Challenges

The roadshow represents Epigral's effort to boost investor confidence and transparency following recent financial challenges. Direct engagement with institutional investors provides a platform for the company to address market concerns, outline its strategic direction, and offer insights into future prospects. This is crucial for shareholders looking for a clearer understanding of Epigral's path forward and its ability to manage market conditions.

Tough Quarter and Expansion Plans

Epigral, an integrated chemical manufacturer, faced a challenging Q3 FY26. Revenue fell 7.5% year-on-year to around ₹597 crore, and net profit dropped 62.2% to ₹39 crore. These results were impacted by lower product prices, higher raw material costs, and inventory issues, which compressed EBITDA margins to 17%. Despite this, Epigral is pushing ahead with significant capacity expansions. Projects aimed at doubling CPVC resin capacity to 150,000 TPA and Epichlorohydrin capacity to 100,000 TPA are slated for commissioning by FY27, focusing on expanding its specialty chemicals business. The company also noted past regulatory issues, including a ₹0.03 crore penalty and a ₹52.52 crore tax assessment notice it intends to challenge.

Looking Ahead: Investor Interaction and Strategy

The roadshow offers a direct channel for Epigral management to communicate with major institutional investors. Participants can expect updated perspectives on the company's strategy for navigating market conditions and achieving profitability. The discussions are likely to shape investor sentiment regarding Epigral's future prospects. Management is also expected to reaffirm its focus on long-term growth through ongoing capacity expansion projects, targeting contributions from FY27.

Potential Risks

Investors should note that the roadshow schedule could change due to company or investor availability. Near-term profitability may continue to be affected by ongoing pressures on product prices and raw material costs. Furthermore, the successful and timely execution of large capital expenditure projects remains critical for Epigral's future growth.

Comparison with Peers

In the specialty chemicals sector, Epigral reported ₹597.12 crore in revenue and ₹39.11 crore in net profit for Q3 FY26. In contrast, Aether Industries posted ₹317.12 crore in revenue and ₹64.48 crore in net profit for the same period. This highlights Epigral's higher revenue but notably lower net profit, reflecting the margin pressures it experienced relative to some competitors.

Key Financial Metrics

Key figures for Epigral's Q3 FY26 include revenue of ₹597.12 crore and a net profit of ₹39.15 crore. EBITDA margins contracted to approximately 17% during the quarter.

What to Watch For

Investors will be monitoring feedback from the roadshow for any shifts in analyst ratings or investor sentiment. Attention will also be on Epigral's Q4 FY26 financial results for indications of recovery. Updates on the progress of the CPVC and Epichlorohydrin capacity expansions, along with management's commentary on market trends and growth drivers, will be key. Developments regarding the tax assessment notice and the company's appeal process will also be important to track.